Systemically administered rhBMP-2 promotes MSC activity and reverses bone and cartilage loss in osteopenic mice

Keyphrases

• Bone Loss 100%
• Bone Morphogenetic protein-2 (BMP-2) 100%
• Osteopetrotic Mice 100%
• Cartilage Loss 100%
• Osteoporosis 83%
• Bone Formation 50%
• Osteopenia 50%
• Apoptosis 33%
• Osteogenic Activity 33%
• Adult Mesenchymal Stem Cells 33%
• Estrogen Deficiency 33%
• Osteogenic Proliferation 33%
• Bone Mass 16%
• High Risk 16%
• Intraperitoneal Injection 16%
• Bone Resorption 16%
• Cell number 16%
• Pathophysiology 16%
• Aged Mice 16%
• Murine Model 16%
• Articular Cartilage 16%
• Osteogenic Differentiation 16%
• Male Mice 16%
• Aging 16%
• Epiphyseal Cartilage 16%
• Bone Turnover 16%
• Osteoinductive 16%
• Anabolic Steroids 16%
• Osteoporosis Model 16%
• Stem Cell Culture 16%
• Good Target 16%
• Systemic Treatment 16%
• Recombinant Human Bone Morphogenetic Protein 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Osteopenia 100%
• Estrogen Deficiency 100%
• Diseases 100%
• Intraperitoneal Injection 50%
• Pathophysiology 50%
• Murine 50%
• Systemic Treatment 50%
• Stem Cell Culture 50%
• Bone Morphogenetic Protein 50%

Biochemistry, Genetics and Molecular Biology

• Ossification 100%
• Osteolysis 66%
• Programmed Cell Death 66%
• Bone Mass 33%
• Bone Morphogenetic Protein 33%
• Stem Cell 33%
• Bone Turnover 33%
• Murine 33%
• Stem Cell Culture 33%